Key Takeaways:
Viridian Therapeutics Inc. is raising $350 million through an upsized stock and convertible debt offering, capitalizing on positive clinical trial results to fund the expansion of its thyroid eye disease (TED) franchise and repay existing debt. The biotech company, which focuses on autoimmune and rare diseases, priced a $225 million offering of 1.75% convertible senior notes due 2032 and a concurrent $125 million sale of 7.35 million shares of common stock at $17.00 each.
The company stated its intention is "to fund market expansion studies for its thyroid eye disease (“TED”) franchise, and to advance the research and development of its earlier pipeline, as well as for working capital and other general corporate purposes."
The common stock was priced at $17.00 per share. The five-year convertible notes will bear an interest rate of 1.75 percent and have an initial conversion price of approximately $24.65 per share, representing a 45 percent premium to the stock offering price. The combined offerings, upsized from an initially proposed $250 million, are expected to close around May 11, 2026, and will provide Viridian with approximately $334.7 million in net proceeds. Underwriters, including Jefferies, Leerink Partners, and Goldman Sachs, have a 30-day option to purchase up to an additional $25.0 million in notes and 1.1 million shares of common stock.
This capital infusion provides Viridian with a significant cash runway to advance its two late-stage TED therapies, veligrotug and elegrobart, which have both recently reported positive data from pivotal Phase 3 trials. The funds will be used to repay all outstanding debt with Hercules Capital Inc., de-risking the company's balance sheet as it prepares for potential commercialization. For investors, the financing dilutes immediate share value but funds the development of a promising pipeline in the competitive TED market, currently dominated by Amgen's Tepezza.
Viridian's primary focus is on its anti-insulin-like growth factor-1 receptor (IGF-1R) candidates for the treatment of Thyroid Eye Disease, a debilitating autoimmune condition. The company's lead intravenous candidate, veligrotug, has met its primary and all secondary endpoints in two global Phase 3 trials, THRIVE and THRIVE-2.
The company is also developing elegrobart as a potential first-in-class subcutaneous treatment for TED, which would offer greater convenience than intravenous infusions. Elegrobart also recently reported positive topline data from its own pivotal Phase 3 trials, REVEAL-1 and REVEAL-2. The successful financing positions Viridian to fund further studies and prepare for potential market entry, challenging existing therapies with a potentially more convenient and effective treatment profile.
The proceeds will also support Viridian's earlier-stage pipeline, which includes an anti-thyroid-stimulating hormone receptor (TSHR) program for TED and Graves’ disease, and a portfolio of neonatal Fc receptor (FcRn) inhibitors for other autoimmune diseases. The successful capital raise, following strong clinical data, strengthens Viridian's competitive position as it moves towards becoming a commercial-stage biotechnology company. The company's ability to secure upsized financing indicates robust investor demand and a positive outlook on its potential to capture a significant share of the multi-billion dollar market for autoimmune therapies.
This article is for informational purposes only and does not constitute investment advice.
